Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 9,926 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single-arm Clear all
Active, not recruiting Phase 1 Interventional

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

NCT00463814
View directory record Official record
Conditions
Tumor, Cancer
Interventions
AZD6244
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Affordable Mobile Robots for the Elderly

NCT02807506
View directory record Official record
Conditions
Aging
Interventions
Mobile Service Robot, Survey
Device · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 31, 2026, 5:27 PM EDT
Recruiting Phase 3 Interventional

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT07059000
View directory record Official record
Conditions
Chronic Primary Immune Thrombocytopenia (ITP)
Interventions
Kedrion IVIG 10%
Biological
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Shirley, New York • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 1 Interventional Results available

A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin

NCT00993044
View directory record Official record
Conditions
Refractory Solid Tumors in Children
Interventions
Irinotecan, Vincristine, Temozolomide, Bevacizumab
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
12 Months to 20 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 31, 2026, 5:27 PM EDT
Terminated Not applicable Interventional

Transcranial Magnetic Stimulation (TMS) in the Treatment of Anorexia Nervosa

NCT05368844
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
rTMS treatment using BrainsWay Model 104 system with H1-Coil, sham TMS using BrainsWay Model 104 system with H1-Coil
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 31, 2026, 5:27 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

NCT04416984
View directory record Official record
Conditions
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Interventions
ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Genetic · Biological · Drug
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
24
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948

NCT06691828
View directory record Official record
Conditions
Healthy Volunteer
Interventions
NX-5948
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies

NCT00975819
View directory record Official record
Conditions
Kaposiform Hemangioendotheliomas, Tufted Angioma, Capillary Venous Lymphatic Malformation, Venous Lymphatic Malformation, Microcystic Lymphatic Malformation, Mucocutaneous Lymphangiomatosis and Thrombocytopenia, Capillary Lymphatic Arterial Venous Malformations, PTEN Overgrowth Syndrome With Vascular Anomaly, Lymphangiectasia Syndromes
Interventions
sirolimus
Drug
Lead sponsor
Denise Martin Adams
Other
Eligibility
Up to 31 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose (BMS-813160) Study

NCT01049165
View directory record Official record
Conditions
Accelerated Intimal Hyperplasia
Interventions
BMS-813160, [14C] BMS-813160, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2011 · Synced Oct 31, 2026, 5:27 PM EDT
Recruiting Not applicable Interventional

Effect of a Humanoid Robot With Virtual Reality Games to Train Arm Function in Children With Cerebral Palsy - THRIVE Trial

NCT06881407
View directory record Official record
Conditions
Cerebral Palsy (CP)
Interventions
Robot, Virtual Reality
Device
Lead sponsor
Georgia State University
Other
Eligibility
5 Years to 21 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Not applicable Interventional

Post Operative Skin Approximation With Cyanoacrylate Based Wound Closure Adhesives

NCT07613892
View directory record Official record
Conditions
Wound Closure, Dehisced Surgical Wounds
Interventions
Evaluating wound closure products to close larger surgical site incisions, Evaluating wound closure products to close smaller surgical site incisions
Device
Lead sponsor
Medline Industries
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Johnstown, Colorado
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects

NCT03792971
View directory record Official record
Conditions
Healthy
Interventions
Dextromethorphan HBr, GC4419
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Tetrahydrocannabinol (THC) and Sleep

NCT03560934
View directory record Official record
Conditions
Sleep, THC, Marijuana, Cannabis
Interventions
Dronabinol
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 34 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 1 Interventional

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

NCT00647764
View directory record Official record
Conditions
Solid Tumor Malignancy, Lymphoid Malignancy (Lymphoma and CLL), Leukemia, Lymphoma
Interventions
SNX-5422 Mesylate Hsp90 inhibitor
Drug
Lead sponsor
Esanex Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Oct 31, 2026, 5:27 PM EDT
Withdrawn Phase 4 Interventional

Adductor Canal Catheter vs Local Infiltration of Analgesia for Total Knee Arthroplasty

NCT02603900
View directory record Official record
Conditions
Acute Pain, Regional Anesthesia Morbidity
Interventions
ropivacaine, bupivacaine, Sham Adductor Canal Catheter, Adductor Canal Catheter
Drug · Device
Lead sponsor
Thomas Jefferson University
Other
Eligibility
40 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 31, 2026, 5:27 PM EDT
Withdrawn Not applicable Interventional

Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer

NCT01983371
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Ferumoxytol, Magnetic Resonance Imaging
Drug · Other
Lead sponsor
Scott Potenta, MD, PhD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 31, 2026, 5:27 PM EDT
Terminated No phase listed Observational Results available

A Post-Market Clinical Evaluation of the ReUnion Reversible Fracture (RFX) System

NCT04089371
View directory record Official record
Conditions
Arthroplasty, Hemiarthroplasty, Shoulder Pain
Interventions
ReUnion Total Shoulder Arthroplasty (TSA), ReUnion Reverse Shoulder Arthroplasty (RSA)
Device
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Peoria, Illinois • Greenville, South Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 2 Interventional Results available

Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy

NCT00505934
View directory record Official record
Conditions
Epilepsy
Interventions
Levetiracetam
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
1 Month to 4 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
San Diego, California • Buffalo, New York • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Oct 31, 2026, 5:27 PM EDT
Withdrawn Phase 4 Interventional

Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation

NCT02198209
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Liraglutide
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.

NCT04111614
View directory record Official record
Conditions
Healthy
Interventions
Tofacitinib tablet, Tofacitinib Oral Solution
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 31, 2026, 5:27 PM EDT
Terminated Phase 3 Interventional Results available

T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)

NCT04128319
View directory record Official record
Conditions
Steroid-Refractory Acute Graft Versus Host Disease
Interventions
T-Guard
Drug
Lead sponsor
Xenikos
Industry
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
24
States / cities
Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 3 Interventional Results available

Optimizing Tobacco Dependence Treatment in the Emergency Department

NCT02896400
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Brief Negotiated Interview (BNI), Nicotine replacement therapy (NRT), CT Smokers Quitline (QL), SmokefreeText (Text)
Behavioral · Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 31, 2026, 5:27 PM EDT
Withdrawn Phase 2 Interventional

Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19

NCT07196306
View directory record Official record
Conditions
COVID, COVID-19, Corona Virus Infection
Interventions
Sarilumab 200 MG/1.14 ML Subcutaneous Solution, Placebo
Drug
Lead sponsor
BayCare Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
Clearwater, Florida • St. Petersburg, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 31, 2026, 5:27 PM EDT
Terminated Phase 3 Interventional

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

NCT04140305
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RPC-1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
56
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 31, 2026, 5:27 PM EDT